About
Renibus Therapeutics is a clinical-stage biopharmaceutical company developing therapies to prevent disease progression and protect against organ damage in cardiovascular, renal, and metabolic diseases, with lead assets including the Phase 3 candidate Veverimer and the cardiac surgery asset RBT-1.
Explore Renibus Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.